Skip to content
Briacell HTML Sitemap
Posts
- BriaCell Adds New Clinical Site To Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
- BriaCell Appoints New York-Based RK Equity Advisors and TrueNorth LifeScience a Corporate Advisor
- BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
- BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.
- Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at SmallCapVoice.com
- BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
- BriaCell Announces the Appointment of Biotechnology Veteran William Williams as New CEO and Director
- BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
- BriaCell Appoints Jamieson Bondarenko to its Board of Directors
- BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences
- BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston
- BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview
- BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study
- BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
- BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™
- BriaCell Completes Manufacturing of New Batch of BriaVax™
- IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
- BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT™
- BriaCell Presenting at Upcoming Cancer Conference
- BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT(TM) Immunotherapy Treatment at SITC Annual Meeting
- BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
- BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
- BriaCell Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients
- BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences
- BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
- BriaCell Expands Targeted Pipeline via Acquisition of Sapientia Pharmaceuticals
- BriaCell to Attend 20th Annual BIO CEO & Investor Conference
- BriaCell Therapeutics Corp. Announces Shares for Debt Issuance
- BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®
- BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling
- BriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
- BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
- BriaCell Appoints Top Oncologist and Opens Second Clinical Site for its Ongoing Clinical Trial in Advanced Breast Cancer
- BriaCell Announces Additional Capital Support by the CEO
- BriaCell Secures License for a Promising Novel Anti-Cancer Agent
- BriaCell Therapeutics Announces Hiring of CFO Gadi Levin; AGM Results
- BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
- BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire
- BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
- BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
- BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
- BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
- BriaCell Provides Clinical Development Update on BriaVax™
- BriaCell Provides A Corporate Update
- BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment
- BriaCell Provides Research Update
- BriaCell To Present at Precision Breast Cancer Conference
- BriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast
- BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million
- BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
- BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation
- BriaCell Announces Proposed Investment by Leading Biotech Funds and Concurrent Non-Brokered Financing for aggregate gross proceeds of up to $4.8 Million
- BriaCell Presents Development Details of Bria-OTS(TM) Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
- BriaCell Adds Third Clinical Site – Led by Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial in Advanced Breast Cancer
- BriaCell Files a Patent Application for its Companion Diagnostic Platform to complement BriaVax™
- BriaCell Appoints Top Social Media Marketing Analyst
- BriaCell advances preparatory work for new Bria-OTS(TM) breast cancer clinical trial
- BriaCell to Present at a Breast Cancer Symposium, and Enters into a Research Agreement with Terasaki Foundation Laboratory
- BriaCell Announces Repricing of Warrants
- BriaCell to Present at the 3rd Annual Biologics World Nordic 2020
- BriaCell Completes Previously Announced Oversubscribed Non-Brokered Private Placement and Concurrent Investment with Leading U.S. Biotech Funds
- BriaCell Announces Investor and Media Outreach Programs
- BriaCell Announces Senior Management Change
- BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board
- BriaCell’s Lead Product Candidate Mechanism of Action Described in a Major Immunology Journal
- UPDATED - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
- BriaCell Announces Warrant Incentive Program
- BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer
- BriaCell to Present Encouraging Clinical Data at AACR 2018
- Dr. Lacher’s interview with GenomeWeb - Dec 2016
- BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update
- Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, is Featured in an Exclusive New Audio Interview with SmallCapVoice.com
- BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
- BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders
- BriaCell Included in the List of Key Players in Immuno-Oncology - Genome Web Interviews BriaCell’s Head of R&D -
- BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
- BriaCell Provides Highlights of Scientific and Clinical Findings at AACR
- BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
- BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting
- BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
- BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
- FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to their Immunotherapy in Patients with Advanced Breast Cancer
- BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference
- BriaCell Moves Forward to Initiate Phase I/IIa Clinical Study for BriaVax™ in Advanced Breast Cancer
- BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
- Expanding Breast Cancer Treatment Options: A Q&A with BriaCell on their Cancer Immunotherapy and their Pipeline
- BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
- BriaCell’s Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
- BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor
- BriaCell Discovers Gene Signature of BriaVax(TM) Cancer Vaccine Consistent With Exceptional Efficacy in Clinical Trial
- BriaCell Provides Clinical Update
- BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)
- BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS(TM) IND
- BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
- BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
- BriaCell Announces C$500,000 Equity Investment by BriaCell Director
- BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
- BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
- October is Breast Cancer Awareness Month - BriaCell is Leading the Fight with its Innovative Technology
- Note from BriaCell Management – October is Breast Cancer Awareness Month
- Hired Dr. M. Lacher –Head of R&D -an expert in immuno-oncology & diagnostics
- BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
- BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering
- BriaCell begins trading on the OTCQB (BCTXF)
- BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
- BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT(TM) Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
- BriaCell CEO Equity Investment Advances Company's Lead Cancer Product and Pipeline Expansion
- Signed Definitive Agreement of Manufacturing of BriaVax at cGMP Facility- UC, Davis Health Center
- BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer
- Hired seasoned biotech veteran Dr. Joseph Wagner as President and Chief Executive Officer
- BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement
- BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
- BriaCell Therapeutics Corp. completes its Initial Public Offering (IPO), & raises $US2.0M, trades at TSX Venture (BCT.V)
- BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer
- Incorporated as a private Delaware company
- BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference
- BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting
- BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
- BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
- Dr. Bill Williams Guest Appearance at “CEO Money” Radio Show
- BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million
- BriaCell’s Lead Product Candidate’s Novel Mechanism of Action Published in a Reputable Immunology Journal
- BriaCell Announces Collaboration with the National Cancer Institute
- BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer
- BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
- BriaCell Files New Patent Application for its Whole-Cell Breast Cancer Vaccine and Companion Diagnostic Platforms
- BRIACELL THERAPEUTICS CORP. CLOSES DEBT FINANCING
- BriaCell Announces $350,000 Equity Investment by Board of Directors
- BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting
- Bill Williams M.D. from BriaCell on CEO Money
- BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
- BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter
- BriaCell Appoints Richard J. Berman to Board of Directors
- BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS(TM) Immunotherapy for Cancer
- BriaCell Announces Closing of Warrant Incentive Program
- BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity
- FDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer
- BriaCell Files Coronavirus Immunotherapy Patent
- BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.
- BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax™ in Patients with Advanced Breast Cancer
- BriaCell Appoints Martin Schmieg to Board of Directors
- BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share
- BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.
- BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR
- BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created "SpinCo" Entity whereby Shareholders to Receive One New Share of "SpinCo" in Addition to Each Current Share of BriaCell Already Held
- BriaCell Files a Patent Application to Protect Additional Cancer Vaccines with Genetic Features Thought to Promote Strong Anti-Tumor Activity
- BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
- BriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual Meeting
- BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
- BriaCell Reports Positive Survival Data in Advanced Metastatic Breast Cancer
- BriaCell Publishes Clinical Findings in 2018 American Society of Clinical Oncology (ASCO) Meeting
- BriaCell Closes CEO Equity Investment
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019
- BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director
- BriaCell CEO Letter to Shareholders
- BriaCell To Attend Biotech Showcase™ 2018
- BriaCell Announces Presentation at the 2021 Keystone Symposia Conference: Emerging Cell Therapies
- BriaCell to Investigate Alleged Illegal Trading of Public Securities
- BriaCell Receives FDA Authorization to Initiate Phase I/IIa Trial of Cell-Based Immunotherapy BriaVax(TM) in Advanced Breast Cancer Patients
- BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT(TM) Combination in Advanced Metastatic Breast Cancer
- BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston
- BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
- BriaCell Presents Clinical Data at 2021 Keystone Symposium
- BriaCell Announces New Patent Issuance, Bria-OTS(TM) IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
- BriaCell Quadruples Progression Free Survival (PFS) in Patient with "Eye-Bulging" Metastatic Breast Cancer
- Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with SmallCapVoice.com
- BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49
- BriaCell Presents Clinical Efficacy Data at ASCO 2024
- BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
- BriaCell Therapeutics Corp. to Present at The MicroCap Conference on June 21st in Toronto at the Sheraton Centre Hotel
- BriaCell Files Patent Application for Novel Therapeutics for Cancer
- ASCO 2018: Interview with Dr. Saveri Bhattacharya on the ongoing Ph I/IIa clinical trial with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer
- BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
- Initial Research Report (by RB Milestone Group) - BriaCell Therapeutics Corp. June 21, 2018
- BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS(TM) in Advanced Metastatic Breast Cancer
- BriaCell Announces Proposed Investment by Leading US Biotech Fund - Company Plans to Seek NASDAQ Uplisting –
- Consolidated Financial Statements For the Years Ended July 31, 2016 and 2015
- BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax™ Phase I/IIa Clinical Trial
- BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS(TM) First in Human Study
- BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
- BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders
- BriaCell Announces Private Placement of up to $600,000
- BriaCell Announces Non-Brokered Private Placement
- BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®
- BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
- BriaCell to Hold Conference Call on Key Clinical Findings; Activities
- BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals
- BriaCell Completes Previously Announced Investment with Leading U.S. Biotech Fund and Non-Brokered Private Placement
- BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
- Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month
- BriaCell Announces Oral and Poster Presentations at ASCO 2024
- BriaCell to Present at Biotech Showcase™ 2020 in San Francisco
- BRIACELL ADDS U.S. BIOTECH VETERAN TO ITS BOARD OF DIRECTORS
- BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer
- The Wall Street Analyzer Interview with Dr. Williams - 2017
- BriaCell Therapeutics Corp. Announces Share Consolidation
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
- BriaCell Announces First Patient Dosed in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Therapeutics Corp. to Clarify Record Date
- BriaCell Announces Pricing of US$25 Million Public Offering and Nasdaq Listing
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
- BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
- BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
- Recording of The Webinar: BriaCell Therapeutics Corporate Update - June 28, 2018
- BriaCell Welcomes BioPharma Industry Experts to its Board of Directors
- BriaCell Completes Share Consolidation
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
- BriaCell Announces Closing of US$25 Million Public Offering
- BriaCell Appoints Contract Research Organization, Cancer Insight, to Manage its Upcoming Phase I/IIa Clinical Trials in Advanced Breast Cancer
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities
- BriaCell Therapeutics Corp. to File Amendment to Management Information Circular
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
- BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
- BriaCell Announces Closing of Non-Brokered Private Placement of $568,444
- BriaCell Launches Its Scientific Advisory Board
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications
- BriaCell Announces Voting Results of the Special Meeting of Shareholders
- BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with "Eye-Bulging" Metastatic Breast Cancer
- BriaCell Doses Second Patient in Phase I/IIa Clinical Study of BriaVax™ in Advanced Breast Cancer
- BriaCell Provides Update on Remarkable Responder
- BriaCell Announces Non-Brokered Private Placement
- BriaCell Appoints the Lead Principal Investigator and First Clinical Site for its Upcoming Phase I/IIa Clinical Trial in Advanced Breast Cancer
- BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting
- BriaCell Closes Oversubscribed Non-Brokered Private Placement
Pages
Skip to content